NDA 202514 · Thea Pharma
Zioptan
Tafluprost · Ophthalmic · Prostaglandin Analog
NovelLast checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Feb 10, 2012
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
31
11 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tafluprost" as an intervention, any sponsor and status, largest first.
- Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01026831 · 643 participants · Start Jan 6, 2010 · Primary completion Sep 17, 2010
Drug: Preservative-Free Tafluprost; Comparator: timolol · For: Open-angle Glaucoma; Ocular Hypertension
- Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesPivotal-lookingCompleted
Santen OyIndustry
NCT01292460 · 600 participants (planned) · Start Feb 2011 · Primary completion Sep 2012
Drug: Timolol/ FDC/ Placebo/ Tafluprost · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Kuopio, Finland; Oulu, Finland
- DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%Pivotal-lookingCompleted
Santen Pharmaceutical Co., Ltd.Industry
NCT01342081 · 489 participants · Start May 2011 · Primary completion Sep 2012
Drug: DE-111 ophthalmic solution; Tafluprost ophthalmic solution 0.0015% and 1 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Osaka, Japan
- Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsPivotal-lookingCompleted
Santen OyIndustry
NCT01306461 · 401 participants · Start Mar 2011 · Primary completion Apr 2012
Drug: Timolol and Tafluprost; Fixed Dose Combination of tafluprost and timolol · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Debrecen, Hungary
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Santen Pharmaceutical Co., Ltd.Industry
NCT03822559 · 219 participants · Start Jan 20, 2019 · Primary completion Apr 4, 2023
Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL; A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL · For: Open-angle Glaucoma, Ocular Hypertension
Sites: Changsha, China; Shanghai, China
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01254604 · 190 participants · Start Dec 1, 2011 · Primary completion May 9, 2013
Drug: Preservative-Free Tafluprost or vehicle; Preservative-Free Timolol maleate · For: Glaucoma; Ocular Hypertension
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsPivotal-lookingCompleted
Santen OyIndustry
NCT01087671 · 185 participants · Start Apr 2010 · Primary completion Oct 2010
Drug: tafluprost · For: Ocular Hypertension; Open-Angle Glaucoma
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye DropsPivotal-lookingCompleted
Santen OyIndustry
NCT00596791 · 150 participants (planned) · Start Jan 2008 · Primary completion Jul 2008
Drug: tafluprost · For: Ocular Hypertension; Open-Angle Glaucoma
Sites: Tampere, Finland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zioptan (Tafluprost/PF)
2024 spending
$8.3M
Beneficiaries
5,075
20,424 claims
Per beneficiary
$1,632
$8.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $9,108,837 |
| 2024 | $8,281,962 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Periocular Adverse Reactions to Omidenepag Isopropyl.
Inoue K, Shiokawa M, Katakura S, et al. · Am J Ophthalmol 2022 · Clinical Trial
- Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.
Sun X, Liu Q, Tang X, et al. · BMC Ophthalmol 2022 · Clinical Trial, Phase IV, Multicenter Study
- Spanish multicenter tafluprost tolerability study.
Milla E, Stirbu O, Rey A, et al. · Br J Ophthalmol 2012 · Clinical Trial, Multicenter Study
- Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
Egorov E, Ropo A · Eur J Ophthalmol 2009 · Clinical Trial, Phase III, Multicenter Study
- Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial.
Brinkman D, McSwiney T, James M · Ir J Med Sci 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Thea Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.